Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
BioNTech SE ADR rises Friday, still underperforms market | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-06 | 2024-03 | -0.41 | N/A | N/A | N/A |
2024-03-20 | 2023-12 | 2.64 | 2.05 | -0.59 | -22.35% |
2023-11-06 | 2023-09 | -0.53 | 0.73 | 1.26 | 237.74% |
2023-11-06 | 2023-09 | -0.53 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.75 | -0.86 | -0.11 | -14.67% |
2023-08-07 | 2023-06 | -0.75 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-16 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-15 | HSBC | Downgrade | Buy | Hold |
2023-08-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-07 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-07-31 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 7.45M | 804.11M | 3.11% |
2023-06-29 | Primecap Management Company | 4.66M | 502.94M | 1.94% |
2023-06-29 | Temasek Holdings (Private) Limited | 4.52M | 487.64M | 1.88% |
2023-06-29 | Flossbach von Storch AG | 3.44M | 371.47M | 1.44% |
2023-06-29 | Artisan Partners Limited Partnership | 2.03M | 219.13M | 0.85% |
2023-06-29 | Blackrock Inc. | 1.73M | 186.84M | 0.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 2.23M | 241.18M | 0.93% |
2023-07-30 | Primecap Odyssey Aggressive Growth Fund | 1.37M | 149.11M | 0.57% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 1.37M | 165.80M | 0.57% |
2023-09-29 | New Perspective Fund Inc | 800.00K | 86.91M | 0.33% |
2023-09-29 | First Trust NYSE Arca Biotechnology Index Fund | 416.94K | 45.30M | 0.17% |
2023-06-29 | Artisan Mid-Cap Fund | 375.33K | 40.51M | 0.16% |
Dividend | Date |
---|---|
2.111 | 2022-06-02 |
-
There is no fathomable reason for $BNTX valuation to be only 62% that of $MRNA. BionTech might be splitting its revenue with Pfizer/ Fosun but it is also selling 4 times Moderna. Half of 4x revenue is still 2x revenue. At minimum $BNTX should have the same market cap as $MRNA. That means it’s stock should be 1.5x present levels, around $350, just to have the same valuation as Moderna. Huge upside sitting here with minimal risk.
-
Dip mean buy chance? lmao
-
It seems overvalued
-
It seems overvalued
-
No one steals your stocks. They are all on the market. Cut this crap! But if you dare to
-
It surely overpriced. Time to sell
-
When the price tumbles, some idiot would say why people sell for a potentially few hundred worth stock lol
-
Party is over
-
-
-
$BNTX is being held back by weak-hearted, “clay-handed” investors who simply don’t have enough belief to hold on to their shares despite all the fantastic news and great numbers being reported by the company. They keep selling, either taking profit on small upticks or panic-selling on the slightest negative news. If only $BNTX shareholders had “diamond-hands” like the punters driving $GME up for no rhyme or reason! Even the level of belief that $NVAX buyers are showing despite no actual vaccine being in the market would be sufficient to drive $BNTX to the moon. And there is simply no reason why $MRNA should have a market valuation that is 1.5x $BNTX. Parity with $MRNA itself should drive the price to $300+.
-
It is expected with good earning for Q1. It is not catalyst anymore
-
Biden this retarded dementia old man just want to ruin everything. Why would people vote for this sucker
-
-
-
-
-
$BNTX
Av Est. EPS: $32.07 (‘21) and $18.69 (‘22)
Av Est. Revenue: $12.29B (‘21) and $7.73B (‘22)
Market Cap @ SP 180: $42.3B
P/E @ SP 180: 9.63 (based on ‘22 EPS)$MRNA
Av Est. EPS: $23.27 (‘21) and $16.58 (‘22)
Av Est. Revenue: $17.46B (‘21) and $13.69B (‘22)
Market Cap @ SP 180: $72.2B
P/E @ SP 180: 10.88 (based on ‘22 EPS)Looks like market is grossly underestimating revenue & EPS for $BNTX. Once revenue and EPS for this and next year for $BNTX becomes clear there will be a major price correction. If $BNTX has higher revenue and higher earnings it should have a higher market cap, so price should be more than 2x that of $MRNA.
-
BioNTech SE ADR rises Friday, still underperforms market
news.google.com •